SCHEMBL25523398

SCHEMBL25523398

Cc1ccc(CNC(C)c2ncccn2)cn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.40
GAA P10253 1/20 0.39
PDE10A Q9Y233 1/20 0.38
MEN1 O00255 1/20 0.38
LMNA P02545 1/20 0.38
KMT2A Q03164 1/20 0.38
NAMPT P43490 1/20 0.36
PDE1A P54750 1/20 0.36
PDE1B Q01064 1/20 0.36
PDE1C Q14123 1/20 0.36
CD274 Q9NZQ7 1/20 0.35
VNN1 O95497 1/20 0.34
HDAC4 P56524 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
DYRK1A Q13627 1/20 0.34
CLK4 Q9HAZ1 1/20 0.34
ALDH1A1 P00352 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25201686 0.81 KDM1A (0.45) ADRB2NAMPTPDE1APDE1BPDE1C
SCHEMBL12779730 0.80 CD274 (0.45) SMN1; SMN2GAAPDE10AMEN1LMNA
SCHEMBL23775042 0.80 KDM1A (0.44) ADRB2
SCHEMBL25523394 0.74 ADRB2 (0.43) ADRB2
SCHEMBL14318800 0.74 CD274 (0.45) SMN1; SMN2GAAPDE10AMEN1LMNA
SCHEMBL7995930 0.74 PDE10A (0.39) ADRB2SMN1; SMN2GAAPDE10AMEN1
SCHEMBL23774892 0.74 LOXL2 (0.50) ADRB2SMN1; SMN2GAAVNN1ALDH1A1
SCHEMBL25228350 0.74 KDM1A (0.45) ADRB2PDE10ADYRK1ACLK4
SCHEMBL25522860 0.72 CXCR4 (0.38) ADRB2SMN1; SMN2KMT2AHDAC6ALDH1A1
SCHEMBL3038971 0.70 GAA (0.45) ADRB2SMN1; SMN2GAAPDE10AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159510-A1 NOVEL PRMT5 INHIBITORS AMGEN INC. (US) 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159510-A1 NOVEL PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 ADRB2 3508/4885SMN1; SMN2 1449/4885GAA 3863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.